Department of Health Professions, Faculty of Health, Psychology, and Social Care, Manchester Metropolitan University, Brooks Building, 53 Bonsall Street, Manchester, M15 6GX, UK.
Rheumatol Int. 2020 Sep;40(9):1385-1398. doi: 10.1007/s00296-020-04597-2. Epub 2020 May 25.
To examine the reported clinical and cost-effectiveness of physiotherapy interventions following total hip replacement (THR). A systematic review was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). MEDLINE, CINAHL, AMED, Scopus, DARE, HTA, and NHS EED databases were searched for studies on clinical and cost-effectiveness of physiotherapy in adults with THR published up to March 2020. Studies meeting the inclusion criteria were identified and key data were extracted. Risk of bias was assessed using the Cochrane Risk of Bias Tool and a Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Data were summarised and combined using random-effect meta-analysis. A total of 1263 studies related to the aim of the review were identified, from which 20 studies met the inclusion criteria and were included in the review. These studies were conducted in Australia (n = 3), Brazil (n = 1), United States of America (USA) (n = 2), France (n = 2), Italy (n = 2), Germany (n = 3), Ireland (n = 1), Norway (n = 2), Canada (n = 1), Japan (n = 1), Denmark (n = 1), and United Kingdom (UK) (n = 1). The duration of follow-up of the included studies was ranged from 2 weeks to 12 months. Physiotherapy interventions were found to be clinically effective for functional performance, hip muscle strength, pain, and range of motion flexion. From the National Health Service perspective, an accelerated physiotherapy programme following THR was cost-effective. The findings of the review suggest that physiotherapy interventions were clinically effective for people with THR. However, questions remain on the pooled cost-effectiveness of physiotherapy interventions, and further research is required to examine this in patients with THR. Future studies are required to examine the cost-effectiveness of these interventions from patients, caregivers, and societal perspectives.Registration Prospero (ID: CRD42018096524).
检查全髋关节置换术(THR)后物理治疗干预的报告临床和成本效益。根据系统评价和荟萃分析的首选报告项目(PRISMA)完成了系统评价。检索了 MEDLINE、CINAHL、AMED、Scopus、DARE、HTA 和 NHS EED 数据库,以查找截至 2020 年 3 月发表的关于成人 THR 物理治疗的临床和成本效益的研究。确定符合纳入标准的研究并提取关键数据。使用 Cochrane 偏倚风险工具和综合健康经济评估报告标准(CHEERS)评估偏倚风险。使用随机效应荟萃分析总结和合并数据。总共确定了 1263 项与审查目的相关的研究,其中 20 项研究符合纳入标准并纳入了审查。这些研究分别在澳大利亚(n=3)、巴西(n=1)、美国(n=2)、法国(n=2)、意大利(n=2)、德国(n=3)、爱尔兰(n=1)、挪威(n=2)、加拿大(n=1)、日本(n=1)、丹麦(n=1)和英国(n=1)进行。纳入研究的随访时间从 2 周到 12 个月不等。物理治疗干预在功能表现、髋关节肌肉力量、疼痛和活动范围屈曲方面被发现具有临床效果。从国家卫生服务的角度来看,THR 后加速物理治疗方案具有成本效益。审查结果表明,物理治疗干预对 THR 患者具有临床效果。然而,对于物理治疗干预的综合成本效益仍存在疑问,需要进一步研究以检查 THR 患者的情况。需要进一步的研究来从患者、护理人员和社会的角度检查这些干预措施的成本效益。注册 Prospero(ID:CRD42018096524)。